Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dimopoulos, Meletios A. | - |
dc.contributor.author | Moreau, Philippe | - |
dc.contributor.author | Iida, Shinsuke | - |
dc.contributor.author | Huang, Shang-Yi | - |
dc.contributor.author | Takezako, Naoki | - |
dc.contributor.author | Chng, Wee Joo | - |
dc.contributor.author | Zahlten-Kumeli, Anita | - |
dc.contributor.author | Sersch, Martina A. | - |
dc.contributor.author | Li, Julia | - |
dc.contributor.author | Huang, Mei | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.date.available | 2020-02-27T02:21:46Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/947 | - |
dc.description.abstract | Carfilzomib is an irreversible proteasome inhibitor used for the treatment of relapsed and/or refractory multiple myeloma (RRMM). We evaluated the efficacy and safety of carfilzomib in subgroups of Asian patients in the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. In ENDEAVOR, patients received carfilzomib twice-weekly (56 mg/m(2)) plus dexamethasone (Kd; n = 56) or bortezomib plus dexamethasone (Vd; n = 57). In A.R.R.O.W., patients received carfilzomib once-weekly (70 mg/m(2), n = 30) or twice-weekly (27 mg/m(2), n = 15) plus dexamethasone. Median progression-free survival (PFS) among Asian patients in ENDEAVOR was longer with Kd than with Vd (14.9 versus 8.8 months; HR 0.599); the overall response rate (ORR) was 80.4% versus 70.2%. Median overall survival (Kd versus Vd) was 47.6 versus 38.8 months (HR 0.856). Median PFS among Asian patients in A.R.R.O.W. was longer for once-weekly versus twice-weekly Kd (16.0 versus 8.4 months; HR 0.628); ORR was 76.7% versus 53.3%. Rates of grade >= 3 adverse events were 89.1% (Kd) and 89.5% (Vd) in ENDEAVOR, and 76.6% (once-weekly Kd) versus 73.3% (twice-weekly Kd) in A.R.R.O.W. Overall, carfilzomib had a favorable benefit-risk profile across both dosing regimens [once-weekly (Kd 70 mg/m(2)) and twice-weekly (Kd 56 mg/m(2))] in Asian patients with RRMM, which was consistent with the results of both parent studies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER JAPAN KK | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | IXAZOMIB | - |
dc.title | Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000487282400012 | - |
dc.identifier.doi | 10.1007/s12185-019-02704-z | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF HEMATOLOGY, v.110, no.4, pp.466 - 473 | - |
dc.identifier.scopusid | 2-s2.0-85070198110 | - |
dc.citation.endPage | 473 | - |
dc.citation.startPage | 466 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.volume | 110 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Carfilzomib | - |
dc.subject.keywordAuthor | Relapsed and | - |
dc.subject.keywordAuthor | or refractory multiple myeloma | - |
dc.subject.keywordAuthor | Asian population | - |
dc.subject.keywordAuthor | Clinical trials | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | IXAZOMIB | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.